SCHEME 1
patents concerning this topic. For instance, semisquara-
mide 6 and derivatives showed potent paralytic activities
(Figure 1).16 Other semisquaramides display smooth
muscle relaxation (7)17 and antimigraine activities.18
In addition, diaminocyclobutenediones have been the
subject of considerable research and resulted in phar-
macologically interesting compounds, such as pibutidine
8, a histamine H2 receptor antagonist19 and EAA-090 9,
a neuroprotectant with potential as a treatment for brain
damage resulting from stroke.20 Besides the above-
mentioned physiological properties of cyclobutenediones,
these compounds also proved to be powerful synthetic
building blocks for the synthesis of a variety of carbo-
and heterocycles, such as quinones, furanones, xantho-
nes, cyclopentenediones, phenols, and 2-pyridones.21
The present report describes the application of N-
(cyclobutylidene)amines in the synthesis of different
semisquarates and semisquaramides. It is surprising that
no monocyclic N-(3-arylcyclobutylidene)alkylamines have
been described so far, which makes the study of these
compounds worthwhile. In addition, halogenated N-
(cyclobutylidene)amines in general have barely been
studied. Besides theoretical calculations,22 only one paper
was found concerning halogenated N-(cyclobutylidene)-
amines. This paper deals with the synthesis of the N-tert-
butylimine of a benzo-annelated 2,2-dichlorocyclobu-
tanone.23 Other publications deal with the synthesis and
reactivity of enamines24 or oximes25 which are a com-
pletely different classes of compounds.
SCHEME 2
Readily available 3-substituted 2,2-dichlorocyclobu-
tanones 1026 were dehalogenated with zinc in acetic acid
prior to the conversion to imines 12 because a direct
imination of dichlorinated cyclobutanones 10 was not
successful and resulted in complex reaction mixtures. In
contrast, dehalogenated cyclobutanones 1127 were easily
(14) Butera, J. A.; Antane, M. M.; Antane, S. A.; Argentieri, T. M.;
Freeden, C.; Graceffa, R. F.; Hirth, B. H.; Jenkins, D.; Lennox, J. R.;
Matelan, E.; Norton, N. W.; Quagliato, D.; Sheldon, J. H.; Spinelli,
W.; Warga, D.; Wojdan, A.; Woods, M. J. Med. Chem. 2000, 43, 1187;
Chem. Abstr. 2000, 132, 317624.
iminated using titanium(IV) chloride as an activating and
dehydrating agent, resulting in new imines 12 (Scheme
1). The reaction of these new compounds with 4.5 equiv
of NCS in refluxing CCl4 for 30 min resulted in a 2,2,4,4-
tetrachlorination toward novel imines 13 in high yields.
To verify whether these tetrachlorinated imines could be
used as precursors for 3-hydroxy-4-phenylcyclobutene-
dione 1,28 N-(2,2,4,4-tetrachloro-3-phenylcyclobutylidene)-
isopropylamine was treated with aqueous oxalic acid,
HCl, or H2SO4.
(15) Seitz, G.; Imming, P. Chem. Rev. 1992, 92, 1227.
(16) Shinada, T.; Nakagawa, Y.; Hayashi, K.; Corzo, G.; Nakajima,
T.; Ohfune, Y. Amino Acids 2003, 24, 293.
(17) Butera, J. A.; Lennox, J. R.; Jenkins, D. J. PCT Int. Appl. WO
2000034230 A1 20000615, 2000; Chem. Abstr. 2000, 133, 43244.
(18) Srinivas, N. R.; Shyu, W. C.; Soong, C. W.; Greene, D. J. Pharm.
Sci. 1998, 87, 1170.
(19) Higuchi, A.; Isobu, Y.; Kijima, H.; Kiuchi, Y.; Saito, T. Jpn Kokai
Tokkyo Koho JP 11092372 A2 19990406, 1999; Chem. Abstr. 1999, 130,
316615.
Much to our surprise, a considerable amount of dehy-
drochlorinated imine 14 was recovered after workup
(Scheme 2). Even when 13a was treated with an excess
of 80% aq H2SO4 at room temperature, a dehydrohalo-
genation occurred toward N-(2,4,4-trichloro-3-phenyl-2-
cyclobutenylidene)isopropylamine 14 which appeared to
be quite stable and was only partially converted to the
hydrolyzed cyclobutenone 15 after 20 h. Eventually, a
complete hydrolysis of imine 13a toward 3-hydroxy-4-
phenylcyclobutenedione 1 was established under very
harsh hydrolytic conditions, i.e., 90% aq H2SO4 at
80-90 °C for 15 h (yield 72%). To develop a most efficient
pathway toward 4-phenylsemisquaric acid 1, attempts
were performed to chlorinate 2,2-dichloro-3-phenylcy-
clobutanone with the use of NCS or trichloroisocyanuric
(20) Childers, W. E., Jr.; Abou-Gharbia, M. A.; Magid, A.; Moyer, J.
A.; Zaleska, M. M. Drugs Future 2002, 27, 633638; Chem. Abstr. 2002,
139, 16866.
(21) (a) Ohno, M.; Yamamoto, Y.; Eguchi, S. Synlett 1998, 1167. (b)
Taing, M.; Moore, H. W. J. Org. Chem. 1996, 61, 329. (c) Sun, L.;
Liebeskind, L. S. J. Am. Chem. Soc. 1996, 118, 12473. (d) Zhang, S.;
Liebeskind, L. S. J. Org. Chem. 1999, 64, 4042. (e) Liebeskind, L. S.;
Fengl, R. W. J. Org. Chem. 1990, 55, 5359 and references therein. (f)
Shinada, T.; Ooyama, Y.; Hayashi, K.-I., Ohfune, Y. Tetrahedron Lett.
2002, 43, 6755.
(22) Ding W.-J.; Fang, D.-C. J. Org. Chem. 2001, 66, 6673.
(23) Roedig, A.; Ganns, E. M. Liebigs Ann. Chem. 1982, 406.
(24) (a) Kristol, D.; Shapiro, R. J. Org. Chem. 1973, 38, 1470. (b)
Madsen, J. O.; Lawesson, S.-O. Tetrahedron 1974, 30, 3481.
(25) Gsell, L.; Gehret, J. C. Eur. Pat. Appl. EP 39308 A1 19811104,
1981; Chem. Abstr. 1981, 96, 85116.
(26) (a) Krepski, L. R.; Hassner, A. J. Org. Chem. 1978, 43, 2879.
(b) Chaumeil, H.; Le Drain, C. Helv. Chim. Acta 1996, 79, 1075. (c)
Cagnon, J. R.; Marchand-Brynaert, J.; Ghosez, L. J. Braz. Chem. Soc.
1996, 7, 371.
(27) (a) Hassner, A.; Dillon, J. L., Jr. J. Org. Chem. 1983, 48, 3382.
(b) Dehmlow, E. V.; Bueker, S. Chem. Ber. 1993, 126, 2759.
(28) Chickos, J. S. J. Org. Chem. 1973, 38, 3642.
4550 J. Org. Chem., Vol. 70, No. 11, 2005